西布曲明减重效应及其影响因素分析  

Effect of sibutramine in reducing body mass and its influencing factors

作　　者：李蓉[1] 李启富[1] 罗蓉[1] 周波[1] 张素华[1] 刘智萍[1] 邓吉容[1] 粟绍初[1] 

机构地区：[1]重庆医科大学附属第一医院内分泌科,重庆市400016

出　　处：《中国临床康复》2005年第7期16-19,共4页Chinese Journal of Clinical Rehabilitation

摘　　要：目的:观察西布曲明治疗单纯性肥胖的疗效,并对影响疗效的相关因素进行探讨。方法:2000-07/2001-09收集207例单纯性肥胖患者,均来自重庆市各社区医疗服务点。纳入标准:经过两周的平衡期(包括行为、运动、平衡饮食控制)后BMI≥27kg/m2;年龄(18～65)岁;女性应未怀孕,非哺乳期;6个月内未使用过影响体质量、食欲、5-羟色胺及去甲肾上腺素代谢的药物。排除标准:继发性肥胖患者;肝、肾功能超过正常值;合并高血压、糖尿病、心血管疾病、胃肠疾病及精神系统疾病。207例患者中138例随机分配入盐酸西布曲明治疗组,69例入安慰剂组。试验为期24周,治疗前及治疗后4,8,12,18及24周测定人体测量学指标。结果:西布曲明组138例中123例,安慰剂组69例中59例完成试验。治疗24周后,西布曲明组体质量平均下降了(4.5±4.7)kg犤下降百分率为(6.0±6.0)%犦,安慰剂组则增高了(0.6±3.0)kg犤增加(0.7±3.7)%犦,两组比较,差异有显著性意义(t=3.145～9.166,P<0.01)。多元逐步回归分析提示西布曲明组治疗24周的体质量下降百分率与性别、年龄、4周体质量下降值相关。女性患者体质量下降了(5.2±4.6)kg,犤(7.0±5.9)%犦,显著高于男性患者犤(2.3±4.4)kg,(2.7±5.1)%,P<0.01犦。患者越年轻,体质量下降的幅度也越大。4周体质量下降≥1%者。AIM:To evaluate the efficacy of sibutramine in treating simple obesity and analyze the influencing factors. METHODS:Totally 207 obese patients, who were recruited from communities of Chongqing city from July 2000 to September 2001,were involved in the study.Inclusion criteria:body mass index(BMI) ≥27 kg/m2 through the balance period(including behavior, sports and balance of diet control) for 2 weeks; aged 18 to 65 years old;females should not be pregnant or in lactation period;had no drugs that influenced body mass, appetite,5-hydroxytryptamine(5-HT) and noradrenaline(NE).Exclusion criteria: secondary obese patients; liver and kidney function over normal value;complicated by hypertension,diabetes mellitus(DM),cardiovascular disease, gastrointestinal diseases and neurological disease.The 207 patients were randomly divided into sibutramine group(n=138) and placebo group(n=69).This trial lasted for 24 weeks.The somatometry parameters were assayed before and 4,8,12,18 and 24 weeks after treatment. RESULTS:There were 123 and 59 patients in the sibutramine group and placebo group respectively who had completed the trial.Twenty-four weeks after treatment, the body mass loss was reduced by(4.5±4.7)kg[(6.0 ±6.0)%]in the sibutramine group, while increased by(0.6±3.0) kg[(0.7±3.7)%]in the placebo group, and there were significant differences between the two groups(t=3.145 to 9.166,P< 0.01).Multiple stepwise regressive analysis showed that the reducing percentage of body mass 24 weeks after treatment was related with age,gender and the body mass 4 weeks after treatment in the sibutramine group.The body mass in female patients was decreased by(5.2±4.6) kg[(7.0±5.9)%],significantly higher than that in male patients [(2.3±4.4) kg,(2.7±5.1)%] (P< 0.01).The younger the patients were, the more greatly the body mass reduced.The patients, whose body mass was reduced by 1%or more,lost obviously more body mass after 24-week treatment. CONCLUSION:Sibutramine can effectively reduce body mass, and the effects are more obv

关 键 词：环丁烷类/治疗应用 肥胖症/治疗 体质量 

分 类 号：R589[医药卫生—内分泌]